[Etiology and pathophysiology of fibromyalgia syndrome].

Neurologische Klinik, Universitätsklinikum Würzburg, Josef-Schneider-Str. 11, 97080, Würzburg, Deutschland.
Der Schmerz (Impact Factor: 1.5). 06/2012; 26(3):259-67.
Source: PubMed

ABSTRACT The scheduled update to the German S3 guidelines on fibromyalgia syndrome (FMS) by the Association of the Scientific Medical Societies ("Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften", AWMF; registration number 041/004) was planned starting in March 2011.
The development of the guidelines was coordinated by the German Interdisciplinary Association for Pain Therapy ("Deutsche Interdisziplinären Vereinigung für Schmerztherapie", DIVS), 9 scientific medical societies and 2 patient self-help organizations. Eight working groups with a total of 50 members were evenly balanced in terms of gender, medical field, potential conflicts of interest and hierarchical position in the medical and scientific fields. Literature searches were performed using the Medline, PsycInfo, Scopus and Cochrane Library databases (until December 2010). The grading of the strength of the evidence followed the scheme of the Oxford Centre for Evidence-Based Medicine.
Current data do not identify distinct etiologic or pathophysiological factors mediating development of FMS. The development of FMS is associated with inflammatory rheumatic diseases (EL2b), with gene polymorphisms of the 5-hydroxytryptamine (HT)(2) receptor (EL3a), lifestyle factors (smoking, obesity, lack of physical activity; EL2b), physical and sexual abuse in childhood and adulthood (EL3a).
FMS is most likely the result of various pathogenetic factors and pathophysiological mechanisms. The English full-text version of this article is available at SpringerLink (under "Supplemental").

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fatigue is a common symptom of numerous acute and chronic diseases, including myalgic encephalomyelitis/chronic fatigue syndrome, multiple sclerosis, heart failure, cancer, and many others. In these multi-system diseases the physiological determinants of enhanced fatigue encompass a combination of metabolic, neurological, and myofibrillar adaptations. Previous research studies have focused on adaptations specific to skeletal muscle and their role in fatigue. However, most have neglected the contribution of physical inactivity in assessing disease syndromes, which, through deconditioning, likely contributes to symptomatic fatigue. In this commentary, we briefly review disease-related muscle phenotypes in the context of whether they relate to the primary disease or whether they develop secondary to reduced physical activity. Knowledge of the etiology of the skeletal muscle adaptations in these conditions and their contribution to fatigue symptoms is important for understanding the utility of exercise rehabilitation as an intervention to alleviate the physiological precipitants of fatigue.
    Biology 09/2014; 3(3):606-622. DOI:10.3390/biology3030606
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Methotrexate is a Disease Modifying Anti Rheumatic Drug (DMARD) we used in the treatment of patients with severe fibromyalgia symptoms. We present two case discussions of low dose methotrexate treatment resulting in dramatic relief of widespread body pain in patients diagnosed with fibromyalgia. These patients had been refractory to prior treatment with opioids, NSAIDs, anti-seizure medications, anti-depressant medications, pregabalin and corticosteroids. Our case reports endorse Sota Omoigui’s theory of pain which states that the origin of all pain is inflammation and the inflammatory response. Low dose methotrexate has unique broad spectrum anti-inflammatory activity that is not found in any other medication. The drug may significantly decrease or resolve generalized body pain associated with fibromyalgia. The use of low dose Methotrexate co-administered with folic acid should be considered as an adjunct to pain medication to help decrease and sometimes eliminate pain and improve other symptoms such as fatigue and disability in fibromyalgia. Limiting factors include the ability of patients to tolerate the medication.
    Rheumatology 01/2014; Omoigui et al., Rheumatology 2014, 4:1(Volume 4 • Issue 1 • 1000129):129.. DOI:10.4172/2161-1149.1000129 · 4.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fibromyalgia syndrome is characterized by chronic generalized pain accompanied by a broad symptomatologic spectrum. Besides chronic fatigue, sleep disturbances, headaches and cognitive dysfunction that are extensively described in the literature, a considerable proportion of patients with fibromyalgia experience gastrointestinal symptoms that are commonly overlooked in the studies that are not specifically dedicated to evaluate these manifestations. Nevertheless, various attempts were undertaken to explore the gastrointestinal dimension of fibromyalgia. Several studies have demonstrated an elevated comorbidity of irritable bowel syndrome (IBS) among patients with fibromyalgia. Other studies have investigated the frequency of presentation of gastrointestinal symptoms in fibromyalgia in a nonspecific approach describing several gastrointestinal complaints frequently reported by these patients such as abdominal pain, dyspepsia and bowel changes, among others. Several underlying mechanisms that require further investigation could serve as potential explanatory hypotheses for the appearance of such manifestations. These include sensitivity to dietary constituents such as gluten, lactose or FODMAPs or alterations in the brain-gut axis as a result of small intestinal bacterial overgrowth or subclinical enteric infections such as giardiasis. The gastrointestinal component of fibromyalgia constitutes a relevant element of the multidisciplinary pathophysiologic mechanisms underlying fibromyalgia that need to be unveiled, as this would contribute to the adequate designation of relevant treatment alternatives corresponding to these manifestations.
    Rheumatology International 08/2014; 35(3). DOI:10.1007/s00296-014-3109-9 · 1.63 Impact Factor


Available from
May 21, 2014